Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis

Autor: Samuel T Workenhe, Akiko Yanagiya, Huy-Dung Hoang, Soroush Tahmasebi, Dana Pearl, Adrian Pelin, John C. Bell, Chadi Zakaria, Karen L. Mossman, Tyson E. Graber, Jaclyn Hearnden, Polen Sean, Tommy Alain, Jian-Jun Jia, Margaret Watson, Louis-Phillipe Leroux, Seyed Mehdi Jafarnejad, Jean-Simon Diallo, Nahum Sonenberg, Maritza Jaramillo, Nathaniel Robichaud, Vinh Tai Truong, Fabrice Le Boeuf

Publikováno v: Zakaria, C, Sean, P, Hoang, H-D, Leroux, L-P, Watson, M, Workenhe, S T, Hearnden, J, Pearl, D, Truong, V T, Robichaud, N, Yanagiya, A, Tahmasebi, S, Jafarnejad, S M, Jia, J-J, Pelin, A, Diallo, J-S, Le Boeuf, F, Bell, J C, Mossman, K L, Graber, T E, Jaramillo, M, Sonenberg, N & Alain, T 2018, ' Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis ', PLoS Pathogens, vol. 14, no. 8, e1007264 . https://doi.org/10.1371/journal.ppat.1007264
PLoS Pathogens
PLoS Pathogens, Public Library of Science, 2018, 14 (8), pp.e1007264. ⟨10.1371/journal.ppat.1007264⟩
PLoS Pathogens, Vol 14, Iss 8, p e1007264 (2018)

International audience; Herpes Simplex Virus 1 (HSV1) is amongst the most clinically advanced oncolytic virus platforms. However, efficient and sustained viral replication within tumours is limiting. Rapamycin can stimulate HSV1 replication in cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c92dee5a0216e1929b4920ce8f0aa3
https://pubmed.ncbi.nlm.nih.gov/30138450